ADYNOVATE®

FDA INDICATION: In adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency) for: on-demand treatment and control of bleeding episodes, and routine prophylaxis to reduce the frequency of bleeding episodes. Package Insert

CLASS: Recombinant, PEGylated

DISTRIBUTOR: Shire

ASSAY SIZE (IU): 250, 500, 1000, 2000

DILUENT SIZE: 5.0 mL

MIXING DEVICE: Baxject II® High Flow

ROOM TEMPERATURE STORAGE: Up to 1 month

HALF-LIFE: 13.43 ± 4.05 hours (12 to <18 years), 14.69 ± 3.79 hours (≥18 years)

OTHER WEBSITES: www.bleedingdisorders.com, adynovate.com